Dr. Rodica Pop-Busui is named President-elect of the American Diabetes Association.
Dr. Eva Feldman becomes the first female recipient of the Robert S. Schwab Award.
We identify pathways in ALS that shed light on ALS mechanisms and therapeutic targets.
February
We oversee a special issue of Neurobiology of Disease focused on brain health.
We publish updated guidelines for the diagnosis and treatment of diabetic neuropathy.
We show that a repurposed FDA-approved drug has major potential as a therapeutic strategy for ALS.
March
We host a NeuroNetwork Mini Symposium:“Protecting Your Brain from Stress” with the Eisenberg Family Depression Center.
Drs. Sarah Elzinga and Evan Reynolds receive K99 Pathway to Independence Awards from the National Institutes of Health (NIH).
We report that specific plasma lipids identify neuropathy risk in obesity.
April
Dr. Kevin Chen is named the next Handleman Emerging Scholar.
Dr. Stephen Goutman and the Pranger ALS Clinic team attend the StrikeOut ALS U-M baseball game and ALS Box Car Derby.
May
Our two ALS reviews are featured on the cover of Lancet Neurology’s 20th Anniversary issue.
Dr. Ben Murdock becomes the first Robert A. Epstein & Joan M. Chernoff-Epstein Emerging Scholar.
June
Andi and Larry Wolfe fund the Wolfe Wellness Initiative for Brain Health and a research professorship.
New undergraduates join the lab for the summer as Tauber Student Interns.
July
Dr. Kevin Chen is awarded a grant from the Alzheimer’s Association to examine the mechanisms of the disease.
Dr. Feldman is named the James W. Albers Distinguished University Professor, one of U-M’s highest honors. Dr. Albers is a longtime mentor who was instrumental in her early career.
August
The NIH awards us an R01 grant to examine mechanisms underlying dietary interventions for neuropathy.
We report that the levels of types of fat in the blood are associated with future development of neuropathy in type 2 diabetes, and that a high-fat diet can impact nerve health in mice.
September
Dr. Feldman publishes a prestigious ALS Seminar article in Lancet.
NeuroNetwork MD/PhD student Rosie Henn successfully defends her dissertation and earns her Ph.D.
We received a new grant from the CDC to further study mechanisms underlying ALS, related to the immune system.
We publish an optimized approach to support long-term survival of stem cell transplants in the brain, which can be important for future clinical trials of stem cell therapies for Alzheimer’s disease.
October
Dr. Eva Feldman presents at the Presidential Symposium of both the American Academy of Neurology (AAN) and American Neurological Association (ANA).
NeuroNetwork investigators present at the final session of the 6-year International Diabetic Neuropathy Consortium in Denmark.
We identify microRNAs in blood and skin cells from ALS subjects that could be leveraged to improve ALS diagnosis and treatment options.
We show work in production occupations is associated with increased ALS risk. This gets a front-page feature in the Detroit Free Press.
November
We host a NeuroNetwork Mini Symposium entitled “A Youth Mental Health Crisis: The Surge After the Surge.”
Dr. Stephanie Eid is awarded the ANA’s Wolfe Research Prize for Identifying New Causes or Novel Treatments of Neuropathy.
Dr. Feldman shares ALS research advances associated with our NIH Director’s Transformative Research Award at the NIH High-Risk, High-Reward research seminar.
December
The Eva L. Feldman MD, PhD, Professorship is established with a gift from Edie Briskin—Dr. Brian Callaghan becomes the inaugural Feldman Professor of Neurology.
The CDC visits our group to discuss our ALS research progress under ongoing and new CDC grants.
Dr. Feldman visits our Australian collaborators as part of our NIH-funded Cognition and Longitudinal Assessment of Risk Factors over 30 Years (CLARiFY) Diabetes Complications Study.
